Seeks to track, before fees and expenses, the Prime Treatments, Testing and Advancements Index.The Index is designed to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases. Eligible companies are U.S. exchange traded companies that are engaged in Treatments, Testing, and/or Advancements Focused Business, which is defined as i) performing research, development, and commercialization of treatments or vaccines for infectious diseases, or ii) the research, development, manufacturing, and provision of biological tests for patients. Prime Indexes determines whether a company is eligible based on the assessment of: i) if a company has one or more vaccines or treatments for infectious diseases in preclinical research, in any phase of U.S. Food and Drug Administration (“FDA”) clinical trials, or in commercial stage and is classified by North American Industry Classification System as either a) “Pharmaceutical and Medicine Manufacturing”, or b) “Research and Development in the Physical, Engineering, and Life Sciences”; or ii) if a company derives more than 50% of its revenue from research, development, manufacturing, and provision of biological tests for patients.
$24.19 +1.02 (4.42%)
As of 05/27/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.